Repeat SBRT for Inoperable Recurrent Lung Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational protocol describes stereotactic re-irradiation for patients with inoperable local recurrence of non-small cell lung cancer or lung metastases after prior curative SBRT. Eligible patients must have a recurrence overlapping the previous 50% isodose, have received a prior SBRT with a biologically equivalent dose ≥75 Gy, be at least 12 months from prior treatment, and have performance status ≤2 with no active or uncontrolled distant metastases. Re-irradiation is delivered with ablative intent in up to 8 fractions, while patients previously treated with conventional radiotherapy or receiving palliative/conventional re-irradiation are excluded. Participating centers are located in Bergamo, Bologna, and Catania, Italy, and outcomes will focus on local control and treatment-related toxicity after stereotactic re-irradiation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inoperable primary non-small cell lung cancer or other metastatic primaries with lung metastases, already treated with radical dose SBRT
* Inoperable local recurrence (defined as a tumor recurrence overlapping the 50% isodose field) confirmed by documented radiographic findings and/or pathological biopsies within the thoracic area
* Patients had previously received curative intent SBRT with a biologically equivalent dose equal or higher than 75 Gy
* Stereotactic reirradiation with ablative purposes up to 8 fractions
* No active distant metastasis or controlled distant metastasis at the time of re-irradiation
* More than 12 months from previous SBRT
* PS ≤ 2

Exclusion Criteria:

* Previous conventional RT
* Reirradiation with palliative doses
* Reirradiation with conventionally fractionated or mildly hypofractionated RT

Where it's running

• AST Papa Giovanni XXIII
  Bergamo, Bergamo, Italy Recruiting
• IRCCS Humanitas Research Hospital
  Rozzano, Milano, Italy Recruiting
• Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi
  Bologna, Bologna, Italy Not yet recruiting
• REM Radioterapia
  Catania, Catania, Italy Not yet recruiting
• Radiation oncology unit, Ospedale San Raffaele
  Milan, Milano, Italy Not yet recruiting
• Radiotherapy Department, Istituto Europeo di Oncologia
  Milan, Milano, Italy Not yet recruiting

Study contacts

• Study coordinator: Davide Franceschini, MD, radiation oncologist
• Email: davide.franceschini@cancercenter.humanitas.it
• Phone: +39 0282247428

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.